Intangible Assets

IMNN appears to have limited proprietary asset protection because no filing evidence provided here shows a durable patent estate, exclusive licenses, or regulatory exclusivity that would block peer replication.

Negative ROIC and ROCE indicate the company is not yet converting any scientific or IP position into economic returns, which weakens evidence that intangibles are supporting pricing power versus peers.

With no disclosed brand, data, or platform asset that customers must use, the company lacks the kind of intangible moat that would sustain retention or margins over 5–10 years.

Compared with established biotech peers that often rely on broader patent portfolios or approved-product exclusivity, IMNN’s current moat evidence is materially thinner and less durable.

Switching Costs

No evidence provided indicates customers are embedded in workflows, contracts, or regulated processes that would make IMNN costly to replace versus peers.

The company’s negative profitability metrics suggest it has not yet built a commercial base where switching frictions could translate into durable retention or pricing power.

In contrast to peers with approved therapies, recurring service models, or installed clinical infrastructure, IMNN does not show observable lock-in that would raise customer defection costs.

Absent product-market scale or entrenched usage, switching costs appear minimal and unlikely to protect margins over the medium term.

Network Effects

No evidence suggests IMNN benefits from user-to-user, data, or ecosystem network effects that would strengthen as adoption rises.

Biotech development assets typically do not create meaningful network effects unless paired with a platform, dataset, or partner ecosystem, none of which is evidenced here.

Compared with peers that may accumulate real-world evidence, trial networks, or platform data advantages, IMNN shows no visible compounding network structure.

Without a self-reinforcing adoption loop, network effects do not appear to contribute to moat durability.

Cost Advantage

Negative ROIC and ROCE imply IMNN is not operating with a cost structure that converts into superior unit economics versus peers.

The provided metrics do not show scale efficiencies, asset productivity, or operating leverage that would support a durable cost advantage.

Compared with larger or later-stage peers that can spread R&D, regulatory, and commercialization costs across more programs, IMNN appears structurally disadvantaged on cost absorption.

There is no evidence here that IMNN can underprice peers while preserving margins, so cost advantage is not a moat driver.

Efficient Scale

IMNN does not appear to operate in a market where its current scale creates a natural monopoly or limits room for efficient competition.

The absence of positive returns and the lack of disclosed commercial scale suggest it has not reached a size where fixed-cost dilution materially protects margins versus peers.

Compared with established peers that may benefit from larger development portfolios or commercial infrastructure, IMNN lacks evidence of scale-based defensibility.

Efficient scale is therefore weak because the company does not yet control a scarce market position that would deter entry or sustain pricing power.

Overall Score

IMNN shows no clear evidence of a durable economic moat versus peers, because the provided metrics and available evidence do not support meaningful intangible assets, switching costs, network effects, cost advantage, or efficient scale.